Physician profile
Stephen A Shore
NPI 1336235183
$6,334.28
in general payments reported to CMS, 2019-2025
60 companies · $2,295 in 2025
The $2,295 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $439 · 2021: $322 · 2022: $261 · 2023: $674 · 2024: $958 · 2025: $2,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,925.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $581.44 | 2019-2025 | Opdivo, Opdualag, Camzyos |
| Shield Therapeutics INC | $564.67 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $437.99 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Novartis Pharmaceuticals Corporation | $348.42 | 2019-2025 | |
| Celgene Corporation | $284.64 | 2019-2025 | Reblozyl, Pomalyst |
| Pharmacyclics LLC, An Abbvie Company | $272.15 | 2019-2023 | Imbruvica, Epkinly |
| Emd Serono, INC. | $268.07 | 2019-2025 | Bavencio |
| Servier Pharmaceuticals LLC | $255.96 | 2021 | |
| Daiichi Sankyo INC. | $253.86 | 2020-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $246.59 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $210.51 | 2023-2025 | Venclexta |
| Genentech USA, INC. | $188.67 | 2019-2023 | Venclexta |
| Janssen Biotech, INC. | $186.41 | 2019-2025 | Carvykti, Rybrevant |
| Pfizer INC. | $180.00 | 2019-2025 | |
| Astellas Pharma US INC | $136.30 | 2022-2025 | Vyloy, Padcev, Xospata |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galvanize Therapeutics, INC | $133.83 | 2025 | Aliya System |
| Incyte Corporation | $133.01 | 2019-2025 | Monjuvi, Pemazyre, Niktimvo |
| Takeda Pharmaceuticals U.S.A., INC. | $131.53 | 2019-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Amgen INC. | $108.54 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Jazz Pharmaceuticals INC. | $105.33 | 2019-2021 | |
| Genmab U.S., INC. | $98.53 | 2023-2025 | Epkinly, Tivdak |
| Eisai INC. | $85.87 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $69.09 | 2019-2025 | Libtayo |
| Genzyme Corporation | $63.59 | 2023-2024 | |
| Kite Pharma, INC. | $62.66 | 2020-2025 | Yescarta |
| Caris Mpi, INC. | $58.40 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $58.06 | 2019-2025 | Trodelvy |
| Mirati Therapeutics, INC. | $50.82 | 2023-2024 | Krazati |
| Lilly USA, LLC | $50.06 | 2025 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $44.98 | 2023-2025 | Ojjaara, Shingrix |
| Exelixis INC. | $39.81 | 2024-2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $36.92 | 2022-2025 | Somatuline Depot, Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $35.78 | 2022-2023 | |
| Stemline Therapeutics INC. | $31.80 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $31.69 | 2019 | |
| Tesaro, INC. | $30.96 | 2019 | |
| Blueprint Medicines Corporation | $29.80 | 2025 | Ayvakit |
| Seagen INC. | $28.02 | 2019 | |
| Tersera Therapeutics LLC | $27.05 | 2025 | Zoladex |
| Teva Pharmaceuticals USA, INC. | $25.05 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $24.90 | 2025 | Ultomiris |
| Array Biopharma INC | $23.47 | 2023 | Comirnaty, Mektovi, Paxlovid |
| Puma Biotechnology, INC. | $22.13 | 2025 | |
| Verastem, INC. | $21.97 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.50 | 2025 | Givlaari |
| Tolmar, INC. | $20.90 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $20.90 | 2025 | Rubraca |
| Sanofi-Aventis U.S. LLC | $19.13 | 2019 | |
| Springworks Therapeutics, INC. | $19.12 | 2024 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $18.55 | 2025 | Romvimza, Qinlock |
| Sobi, INC | $17.96 | 2025 | |
| Beigene USA, INC. | $17.33 | 2025 | Tevimbra |
| Sumitomo Pharma America, INC. | $17.10 | 2024 | Orgovyx |
| Adc Therapeutics America, INC. | $15.87 | 2023 | |
| Tactile Systems Technology INC | $15.50 | 2020 | |
| Beone Medicines USA, INC. | $13.67 | 2025 | Tevimbra |
| Advanced Accelerator Applications | $13.50 | 2020 | |
| Foundation Medicine, INC. | $12.50 | 2020 | |
| Aurobindo Pharma USA, INC. | $11.42 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Shore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.